BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
4.655
+0.435 (10.31%)
At close: Jun 4, 2025, 4:00 PM
4.697
+0.042 (0.91%)
Pre-market: Jun 5, 2025, 8:00 AM EDT

BioLineRx Statistics

Total Valuation

BioLineRx has a market cap or net worth of $16.83 million. The enterprise value is $3.31 million.

Market Cap 16.83M
Enterprise Value 3.31M

Important Dates

The last earnings date was Tuesday, May 27, 2025, before market open.

Earnings Date May 27, 2025
Ex-Dividend Date n/a

Share Statistics

BioLineRx has 2.23 billion shares outstanding. The number of shares has increased by 47.46% in one year.

Current Share Class n/a
Shares Outstanding 2.23B
Shares Change (YoY) +47.46%
Shares Change (QoQ) +69.54%
Owned by Insiders (%) n/a
Owned by Institutions (%) n/a
Float 2.13B

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 0.75
Forward PS n/a
PB Ratio 0.81
P/TBV Ratio 1.61
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 0.15
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 2.27, with a Debt / Equity ratio of 0.66.

Current Ratio 2.27
Quick Ratio 2.02
Debt / Equity 0.66
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -1.95

Financial Efficiency

Return on equity (ROE) is -20.03% and return on invested capital (ROIC) is -35.44%.

Return on Equity (ROE) -20.03%
Return on Assets (ROA) -21.98%
Return on Invested Capital (ROIC) -35.44%
Return on Capital Employed (ROCE) -56.72%
Revenue Per Employee $797,857
Profits Per Employee -$121,357
Employee Count 28
Asset Turnover 0.47
Inventory Turnover 2.53

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -84.15% in the last 52 weeks. The beta is 0.86, so BioLineRx's price volatility has been lower than the market average.

Beta (5Y) 0.86
52-Week Price Change -84.15%
50-Day Moving Average 3.25
200-Day Moving Average 10.73
Relative Strength Index (RSI) 64.25
Average Volume (20 Days) 1,916,204

Short Selling Information

Short Interest 181,450
Short Previous Month 198,765
Short % of Shares Out 4.89%
Short % of Float n/a
Short Ratio (days to cover) 10.35

Income Statement

In the last 12 months, BioLineRx had revenue of $22.34 million and -$3.40 million in losses. Loss per share was -$0.00.

Revenue 22.34M
Gross Profit 14.50M
Operating Income -16.72M
Pretax Income -49.15M
Net Income -3.40M
EBITDA -14.00M
EBIT -16.72M
Loss Per Share -$0.00
Full Income Statement

Balance Sheet

The company has $26.37 million in cash and $13.74 million in debt, giving a net cash position of $12.63 million or $0.01 per share.

Cash & Cash Equivalents 26.37M
Total Debt 13.74M
Net Cash 12.63M
Net Cash Per Share $0.01
Equity (Book Value) 20.86M
Book Value Per Share 0.01
Working Capital 17.89M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$32.36 million and capital expenditures -$21,000, giving a free cash flow of -$32.38 million.

Operating Cash Flow -32.36M
Capital Expenditures -21,000
Free Cash Flow -32.38M
FCF Per Share -$0.01
Full Cash Flow Statement

Margins

Gross margin is 64.90%, with operating and profit margins of -74.85% and -15.21%.

Gross Margin 64.90%
Operating Margin -74.85%
Pretax Margin -15.21%
Profit Margin -15.21%
EBITDA Margin -62.67%
EBIT Margin -74.85%
FCF Margin n/a

Dividends & Yields

BioLineRx does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -47.46%
Shareholder Yield -47.46%
Earnings Yield -20.19%
FCF Yield -192.34%

Analyst Forecast

The average price target for BioLineRx is $19.00, which is 308.16% higher than the current price. The consensus rating is "Strong Buy".

Price Target $19.00
Price Target Difference 308.16%
Analyst Consensus Strong Buy
Analyst Count 2
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on January 30, 2025. It was a reverse split with a ratio of 0.025:1.

Last Split Date Jan 30, 2025
Split Type Reverse
Split Ratio 0.025:1

Scores

BioLineRx has an Altman Z-Score of -11.89 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -11.89
Piotroski F-Score 3